A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies

Rathod, Lalaji; Kapadia, Rakhee; Sawant, Krutika

doi:10.1016/j.msec.2016.10.017

Cited by 45 publications

(22 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ACZ loaded Eudragit nanoparticles and ocular insert demonstrated substantial reduction in IOP and improved ocular tolerability when compared to ACZ suspension in an in vivo study. 111 …”

Section: Nanotechnology Approach In Medicinementioning

confidence: 99%

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Kwon¹,

Kim²,

Khang³

et al. 2020

IJN

View full text Add to dashboard Cite

Glaucoma is a group of diseases characterized by progressive degeneration of retinal ganglion cells, leading to irreversible blindness. Currently, intraocular pressure reduction is the only established treatment available for glaucoma. With this treatment, the progression of the disease can only be delayed and there is no recovery. In addition, the commercially available eye drops have the disadvantage of low compliance and short therapeutic time, while glaucoma surgery always has the risk of failure due to wound fibrosis. Nanotechnology can overcome the limitations of the current treatment through the encapsulation and conjugation of drugs used for lowering intraocular pressure and antifibrotic agents using biodegradable or biocompatible nanoparticles for the sustained release of the drugs to protect the damaged ocular cells. Furthermore, using nanotechnology, treatment can be administered in various forms, including eye drops, contact lens, and ocular inserts, according to the convenience of the patients. Despite the promising results of delaying the progression of glaucoma, the regeneration of damaged ocular cells, including trabecular meshwork and retinal ganglion cells, is another critical hurdle to overcome. Bone marrow-derived mesenchymal stem cells and Müller glia cells can secrete neurogenic factors that trigger the regeneration of associated cells, including trabecular meshwork and retinal ganglion cells. In conclusion, this review highlights the potential therapeutic applications of nanotechnology- and stem cell-based methods that can be employed for the protection and regeneration of ocular cells.

show abstract

“…ACZ loaded Eudragit nanoparticles and ocular insert demonstrated substantial reduction in IOP and improved ocular tolerability when compared to ACZ suspension in an in vivo study. 111 …”

Section: Nanotechnology Approach In Medicinementioning

confidence: 99%

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Kwon¹,

Kim²,

Khang³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Acetazolamide-Eudragit ® nanoparticles were prepared by the solvent diffusion nanoprecipitation technique. Initial burst release during 2 h (because of both free drug and surface-adsorbed drug) was followed by a sustained drug release (a diffusive drug release from the Eudragit ® matrix) [ 145 ]. Transcorneal permeation study showed higher permeation of acetazolamide after 8 h with nanoparticles, size of 103.23 nm and zeta potential of −29.70 to −45.75 mV (74.50 ± 2.20 mg/cm 2 ) compared with the eye drops (20.08 ± 3.12 mg/cm 2 ) and suspension (16.03 ± 2.14 mg/cm 2 ), whereas nanoparticles did not show any side effects on the corneal surface.…”

Section: Novel Drug Delivery Systemsmentioning

confidence: 99%

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

et al. 2020

View full text Add to dashboard Cite

Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

show abstract

“…50 The dialysis membrane was fitted into a Franz diffusion cell having an acceptor capacity of 20 mL filled with PBS (pH 7.4) and rotating at 100 rpm, and the temperature of the surrounding medium was adjusted to 32°C. 51,52 One drop of the OIG formula, one insert of the selected lyophilized formula, or an equivalent volume of the drug solution in PBS was added to 2 mL artificial tears and the diluted samples were filled into the donor compartment.…”

Section: In Vitro Releasementioning

confidence: 99%

Tailored nanostructured platforms for boosting transcorneal permeation: Box–Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization

Elsayed¹,

Sayed²

2017

IJN

View full text Add to dashboard Cite

Ocular drug delivery systems suffer from rapid drainage, intractable corneal permeation and short dosing intervals. Transcorneal drug permeation could increase the drug availability and efficiency in the aqueous humor. The aim of this study was to develop and optimize nanostructured formulations to provide accurate doses, long contact time and enhanced drug permeation. Nanovesicles were designed based on Box–Behnken model and prepared using the thin film hydration technique. The formed nanodispersions were evaluated by measuring the particle size, polydispersity index, zeta potential, entrapment efficiency and gelation temperature. The obtained desirability values were utilized to develop an optimized nanostructured in situ gel and insert. The optimized formulations were imaged by transmission and scanning electron microscopes. In addition, rheological characters, in vitro drug diffusion, ex vivo and in vivo permeation and safety of the optimized formulation were investigated. The optimized insert formulation was found to have a relatively lower viscosity, higher diffusion, ex vivo and in vivo permeation, when compared to the optimized in situ gel. So, the lyophilized nanostructured insert could be considered as a promising carrier and transporter for drugs across the cornea with high biocompatibility and effectiveness.

show abstract

A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies

Cited by 45 publications

References 46 publications

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Tailored nanostructured platforms for boosting transcorneal permeation: Box–Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization

Contact Info

Product

Resources

About

A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies

Cited by 45 publications

References 46 publications

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

<p>Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment</p>

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Tailored nanostructured platforms for boosting transcorneal permeation: Box&ndash;Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization

Contact Info

Product

Resources

About

Tailored nanostructured platforms for boosting transcorneal permeation: Box–Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization